Onconova Therapeutics (NASDAQ:ONTX) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Onconova Therapeutics (NASDAQ:ONTX) in a research note released on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Onconova Therapeutics Stock Performance

Onconova Therapeutics has a 1 year low of $0.55 and a 1 year high of $1.45. The firm has a market cap of $20.90 million, a PE ratio of -1.09 and a beta of 1.38. The firm’s 50-day moving average price is $0.82 and its two-hundred day moving average price is $0.74.

Hedge Funds Weigh In On Onconova Therapeutics

A number of hedge funds have recently modified their holdings of ONTX. Renaissance Technologies LLC grew its holdings in shares of Onconova Therapeutics by 140.8% in the 1st quarter. Renaissance Technologies LLC now owns 321,743 shares of the biopharmaceutical company’s stock worth $592,000 after acquiring an additional 188,116 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Onconova Therapeutics by 21.7% in the 3rd quarter. Vanguard Group Inc. now owns 622,958 shares of the biopharmaceutical company’s stock worth $549,000 after acquiring an additional 110,965 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Onconova Therapeutics by 154.6% in the 2nd quarter. Millennium Management LLC now owns 61,390 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 37,275 shares during the last quarter. Finally, Beacon Pointe Advisors LLC grew its holdings in shares of Onconova Therapeutics by 147.0% in the 1st quarter. Beacon Pointe Advisors LLC now owns 46,027 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 27,396 shares during the last quarter. 7.95% of the stock is currently owned by institutional investors and hedge funds.

About Onconova Therapeutics

Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer.